Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Head and Neck NeoplasmsHead and Neck LymphedemaHead and Neck Cancer
Interventions
DEVICE

Head and neck garments for pneumatic compression device

Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema

DRUG

NIRFLI with ICG

Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.

Trial Locations (1)

77030

UT Health Science Center at Houston, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Tactile Medical

INDUSTRY

NCT02946021 - Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema | Biotech Hunter | Biotech Hunter